Stockscreener 앱 받기
6.56
2.53%
-0.17
시간 외 거래:
6.58
0.02
+0.30%
전일 마감가:
$6.73
열려 있는:
$6.8
하루 거래량:
73,849
Relative Volume:
1.10
시가총액:
$109.72M
수익:
-
순이익/손실:
$-14.88M
주가수익비율:
-6.6939
EPS:
-0.98
순현금흐름:
$-10.29M
1주 성능:
+6.67%
1개월 성능:
-1.65%
6개월 성능:
-2.53%
1년 성능:
+12.52%
1일 변동 폭
$6.41
$6.80
1주일 범위
$6.05
$7.30
52주 변동 폭
$4.65
$10.24
Coya Therapeutics Inc Stock (COYA) Company Profile
명칭
Coya Therapeutics Inc
전화
650.739.3939
주소
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
COYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
6.56 | 112.56M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Lake Street | Buy |
| 2024-12-04 | 개시 | D. Boral Capital | Buy |
Coya Therapeutics Inc 주식(COYA)의 최신 뉴스
Can Coya Therapeutics Inc. hit a new high this monthJuly 2025 Decliners & Target Return Focused Picks - Newser
What Fibonacci levels say about Coya Therapeutics Inc. reboundQuarterly Profit Report & High Conviction Buy Zone Alerts - Newser
Published on: 2025-08-27 10:39:29 - Newser
Coya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy? - zacks.com
Applying Elliott Wave Theory to Coya Therapeutics Inc.July 2025 Intraday Action & AI Driven Stock Movement Reports - Newser
Tools to monitor Coya Therapeutics Inc. recovery probabilityJuly 2025 Trends & Free Low Drawdown Momentum Trade Ideas - Newser
Trend Dashboard Flags Coya Therapeutics Inc. As Potential Swing Trade getLinesFromResByArray error: size == 0 - kangso.co.kr
Will Coya Therapeutics Inc. stock recover after recent drop2025 Valuation Update & Growth-Oriented Investment Plans - Newser
Analyzing net buyer seller activity in Coya Therapeutics Inc.Share Buyback & AI Powered Market Entry Ideas - Newser
Coya Therapeutics shares fall 8.24% intraday despite FDA acceptance of IND application for COYA 302. - AInvest
What's Going On With Coya Therapeutics Stock? - Benzinga
Coya Therapeutics stock soars after FDA accepts IND for ALS treatment - Investing.com Australia
Coya Therapeutics' FDA-Accepted IND for COYA 302: A Catalyst for ALS Therapy Innovation and Investment Potential - AInvest
Coya Therapeutics announces FDA acceptance of investigational new drug (IND) application - MarketScreener
Coya Therapeutics and the FDA IND Acceptance: A Pivotal Step in the Race for ALS Treatment Innovation - AInvest
Coya Therapeutics Receives FDA Approval for COYA 302 ALS Treatment Trial - AInvest
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - PR Newswire
Positive Outlook for Coya Therapeutics Amid Promising Developments and Financial Stability - TipRanks
Using Python tools to backtest Coya Therapeutics Inc. strategies2025 Retail Activity & Low Drawdown Trading Techniques - Newser
Can swing trading help recover from Coya Therapeutics Inc. lossesPortfolio Update Summary & Free Risk Controlled Daily Trade Plans - Newser
How much upside does Coya Therapeutics Inc. haveMarket Risk Report & Real-Time Chart Pattern Alerts - theviewers.co.kr
Is Coya Therapeutics Inc. part of any ETFAnalyst Downgrade & Precise Entry and Exit Recommendations - theviewers.co.kr
Is Coya Therapeutics Inc. in a long term uptrendJuly 2025 Drop Watch & Consistent Return Strategy Ideas - sundaytimes.kr
Is Coya Therapeutics Inc. trending in predictive chart modelsPortfolio Growth Summary & Real-Time Stock Price Movement Reports - Newser
Understanding Coya Therapeutics Inc.’s price movementWeekly Gains Report & Weekly Watchlist for Hot Stocks - Newser
Is Coya Therapeutics Inc. stock ready for a breakoutJuly 2025 Volume & High Accuracy Swing Entry Alerts - Newser
How Resilient Is Coya Therapeutics Inc. Stock During Economic Downturns2025 Macro Impact & Daily Entry Point Trade Alerts - Newser
Applying Wyckoff theory to Coya Therapeutics Inc. stockWeekly Market Summary & Daily Growth Stock Tips - Newser
How volatile is Coya Therapeutics Inc. stockPortfolio Growth Summary & Weekly High Conviction Ideas - newsyoung.net
Why Coya Therapeutics Inc. stock attracts strong analyst attentionRate Hike & Daily Technical Stock Forecast Reports - 선데이타임즈
Published on: 2025-08-16 02:30:48 - newsyoung.net
Regulatory Risk and Reward: Navigating FDA Delays in the ALS Therapeutics Landscape - AInvest
Coya Therapeutics reports Q2 EPS (36c), consensus (43c) - MSN
Coya Therapeutics 2025 Q2 Earnings Sharp Loss Widens, Revenue Collapses - AInvest
Coya Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates - MSN
Coya Therapeutics shares rise 2.46% after-hours after announcing participation in H.C. Wainwright 3rd Annual BioConnect Conference. - AInvest
Coya Therapeutics Inc. recovery potential after sell offStock Surge & Community Consensus Stock Picks - Newser
Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update - BioSpace
Coya Therapeutics Reports Increased Losses Amid Development Focus - TipRanks
Coya Therapeutics' $75M Mixed Shelf: Fueling Neuroinflammation Breakthroughs in ALS, Alzheimer's, and Dementia - AInvest
Coya Therapeutics Files $75 Million Mixed Shelf and Reports Q2 Earnings - AInvest
Coya Therapeutics Files $75 Million Mixed Shelf - MarketScreener
Coya Therapeutics Highlights Q2 2025 Financial Results - TipRanks
Coya Therapeutics, Inc. SEC 10-Q Report - TradingView
Coya Therapeutics Inc (COYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
8.06%
자본화:
|
볼륨(24시간):